- |||||||||| YPEG-filgrastim (YPEG-rhG-CSF) / Xiamen Amoytop Biotech
Trial completion: Safety and Efficacy of YPEG-rhG-CSF in Cancer Patients Receiving Chemotherapy (clinicaltrials.gov) - Jul 17, 2018 P2, N=80, Completed, Recruiting --> Active, not recruiting | Trial completion date: Oct 2019 --> Oct 2018 | Trial primary completion date: Oct 2019 --> Oct 2018 Active, not recruiting --> Completed
- |||||||||| Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Diagnostic assay: Determining the Etiology of Febrile Neutropenia Using the Karius Sequencing-based Infectious Disease Diagnostic Assay (clinicaltrials.gov) - Mar 6, 2018
P=N/A, N=57, Active, not recruiting, Active, not recruiting --> Completed | Trial completion date: May 2020 --> Apr 2018 | Trial primary completion date: May 2019 --> Apr 2018 Recruiting --> Active, not recruiting | N=100 --> 57 | Trial completion date: Dec 2017 --> Jul 2018 | Trial primary completion date: Jul 2017 --> Jul 2018
- |||||||||| YPEG-filgrastim (YPEG-rhG-CSF) / Xiamen Amoytop Biotech
Enrollment closed, Trial primary completion date: Safety and Efficacy of YPEG-rhG-CSF in Cancer Patients Receiving Chemotherapy (clinicaltrials.gov) - Mar 29, 2017 P2, N=80, Active, not recruiting, Recruiting --> Completed | N=128 --> 161 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2017 --> Mar 2017
- |||||||||| GW003 (balugrastim biosimilar) / Mabwell (Shanghai) Biosci
Trial primary completion date: Tolerability and Pharmacokinetics(PK)/Pharmacodynamics(PD) Study of GW003 in Healthy Subjects (clinicaltrials.gov) - Sep 8, 2016 P1, N=30, Recruiting, N=100 --> 2 | Not yet recruiting --> Terminated | Trial primary completion date: Oct 2017 --> Jun 2016; No longer aligned with the revised clinical development plan and commercial strategy Trial primary completion date: Jun 2016 --> Dec 2016
|